This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2002 Mar 1;20(5):1158-60.

doi: 10.1200/JCO.2002.20.5.1158.

Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?

Stephen A Cannistra

PMID: 11870154
DOI: 10.1200/JCO.2002.20.5.1158

Editorial

Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?

Stephen A Cannistra. J Clin Oncol. 2002.

. 2002 Mar 1;20(5):1158-60.

doi: 10.1200/JCO.2002.20.5.1158.

Author

Stephen A Cannistra

PMID: 11870154
DOI: 10.1200/JCO.2002.20.5.1158

No abstract available

PubMed Disclaimer

Comment on

Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
Cantù MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell'Anna T, Torri V, Colombo N. Cantù MG, et al. J Clin Oncol. 2002 Mar 1;20(5):1232-7. doi: 10.1200/JCO.2002.20.5.1232. J Clin Oncol. 2002. PMID: 11870165 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information